SMGr up Choriocarcinoma Syndrome: Bleeding of Distant Metastatic Tumors from a Testicular Germ Cell Tumor Yee-Huang Ku1, Huwi-Chun Chao2 and Wen-Liang Yu2, 3* 1Division of Infectious Disease, Department of Internal Medicine, Chi Mei Medical Center- Liouying, Tainan City, Taiwan 2Department of Intensive Care Medicine, Chi Mei Medical Center, Tainan City, Taiwan 3Department of Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei City, Taiwan *Corresponding author: : Wen-Liang Yu, Department of Intensive Care Medicine, Chi Mei Medical Center, N0. 901 Chuang Hwa Road, Yung Kang District, 710 Tainan City, Taiwan, Tel: +886-6-281-2811, ext. 52605; Fax: +886-6-251-7849, Email:
[email protected] Published Date: August 28, 2018 ABSTRACT The massive hemorrhage at metastatic sites distant from a testicular choriocarcinoma is called choriocarcinoma syndrome. The syndrome occurs mostly common in patients with lung or brain metastases, developing complication of acute pulmonary or cerebral hemorrhage respectively, and that indicates a rapidly progressive and high-component choriocarcinoma within the testicular tumors. The choriocarcinoma syndrome usually happens before and during the onset of systemic treatment with chemotherapy. Choriocarcinoma is a unique and aggressive germ cell malignancy, and these patients require early aggressive treatment to improve their chance of survival. The β-human chorionic gonadotropin (β-hCG) is a well-established marker for screening choriocarcinoma. Successful treatment should incorporate a radical orchiectomy, of syncytiotrophoblast proliferation and marked elevation of serum β-hCG level is a useful tool retroperitoneal lymph node dissection, and chemotherapy. Standard induction chemotherapy regimen includes bleomycin, etoposide and cisplatin. Treatment should be directed towards a goal of tumor marker normalization, and shrinkage of tumor size.